217 related articles for article (PubMed ID: 12710131)
21. Nucleolin protein expression in cutaneous melanocytic lesions.
Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
[TBL] [Abstract][Full Text] [Related]
22. Differential versican isoforms and aggrecan expression in the chicken embryo aorta.
Arciniegas E; Neves CY; Candelle D; Parada D
Anat Rec A Discov Mol Cell Evol Biol; 2004 Jul; 279(1):592-600. PubMed ID: 15224401
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
24. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
25. [Intraepidermal distribution patterns of melanocytes in the melanocytic lesions on the sole: proposed criteria for histopathologic diagnosis of plantar malignant melanoma in situ].
Saida T; Yoshida N
Nihon Hifuka Gakkai Zasshi; 1989 Apr; 99(5):553-60. PubMed ID: 2585770
[TBL] [Abstract][Full Text] [Related]
26. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
27. Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals.
Rettig WJ; Real FX; Spengler BA; Biedler JL; Old LJ
Science; 1986 Mar; 231(4743):1281-4. PubMed ID: 3633135
[TBL] [Abstract][Full Text] [Related]
28. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.
Gambichler T; Grothe S; Rotterdam S; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 Jun; 131(6):782-7. PubMed ID: 19461083
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
[TBL] [Abstract][Full Text] [Related]
30. Clinico-pathological impact of fibroplasia in melanocytic nevi: a critical revision of 209 cases.
Cesinaro AM
APMIS; 2012 Aug; 120(8):658-65. PubMed ID: 22779689
[TBL] [Abstract][Full Text] [Related]
31. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
32. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
33. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion.
Mukaratirwa S; van Ederen AM; Gruys E; Nederbragt H
J Comp Pathol; 2004 Nov; 131(4):259-70. PubMed ID: 15511534
[TBL] [Abstract][Full Text] [Related]
34. Versican.
Lebaron RG
Perspect Dev Neurobiol; 1996; 3(4):261-71. PubMed ID: 9117259
[TBL] [Abstract][Full Text] [Related]
35. Molecular aspects of melanocytic dysplastic nevi.
Hussein MR; Wood GS
J Mol Diagn; 2002 May; 4(2):71-80. PubMed ID: 11986397
[TBL] [Abstract][Full Text] [Related]
36. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
37. Dysplastic nevi in relation to superficial spreading melanoma.
Titus-Ernstoff L; Barnhill RL; Duray PH; Ernstoff MS; Kirkwood JM
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):99-101. PubMed ID: 8467253
[TBL] [Abstract][Full Text] [Related]
38. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
39. Expression of proteoglycans and glycosaminoglycans in angiofibroma and fibrous plaque skin lesions from patients with tuberous sclerosis.
Papakonstantinou E; Dionyssopoulos A; Pesintzaki C; Minas A; Karakiulakis G
Arch Dermatol Res; 2003 Aug; 295(4):138-45. PubMed ID: 12844226
[TBL] [Abstract][Full Text] [Related]
40. Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi ("Spark's" nevi).
Ko CJ; McNiff JM; Glusac EJ
J Cutan Pathol; 2009 Oct; 36(10):1063-8. PubMed ID: 19187111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
